Cascading responses of stimuli-responsive materials

Responsiveness to stimuli is important in daily life: natural biological activity is governed by continuous stimulus responsiveness. The design of stimuli-responsive materials is required for the development of advanced sensing systems. Although fully controlled stimuli-responsive systems have been constructed in nature, artificial systems remain a challenge. Conventional stimuli-responsive materials show direct responsiveness to an applied stimulus (Stimulus 1), with structural changes in their molecules and organized states. This feature article focuses on cascading responses as a new concept for integrating stimuli-responsive material design. In cascading responses, an original stimulus (Stimulus 1) is converted into other stimuli (Stimulus 2, 3, …, N) through successive conversions. Stimulus N provides the eventual output response. Integration of multiple stimuli-responsive materials is required to achieve cascading responses. Although cascade, domino, and tandem chemical reactions have been reported at the molecular level, they are not used for materials with higher organized structures. In this article, we introduce functional carriers and sensors based on cascading responses as model cases. The concept of cascading responses enables the achievement of transscale responsivity and sensitivity, which are not directly induced by the original stimulus or its responsive material, for the development of advanced dynamic functional materials.

Carbonic Anhydrase Variants Catalyze the Reduction of Dialkyl Ketones with High Enantioselectivity

Human carbonic anhydrase II (hCAII) naturally catalyzes the reaction between two achiral molecules-water and carbon dioxide-to yield the achiral product carbonic acid through a zinc hydroxide intermediate. We have previously shown that a zinc hydride, instead of a hydroxide, can be generated in this enzyme to create a catalyst for the reduction of aryl ketones. Dialkyl ketones are more challenging to reduce, and the enantioselective reduction of dialkyl ketones with two alkyl groups that are similar in size and electronic properties, is a particularly challenging transformation to achieve with high activity and selectivity. Here, we show that hCAII, as well as a double mutant of it, catalyzes the enantioselective reduction of dialkyl ketones with high yields and enantioselectivities, even when the two alkyl groups are similar in size. We also show that variants of hCAII catalyze the site-selective reduction of one ketone over the other in an unsymmetrical aliphatic diketone. Computational docking of a dialkyl ketone to variants of hCAII containing the zinc hydride provides insights into the origins of the reactivity of various substrates and the high enantioselectivity of the transformations and show how a confined environment can control the enantioselectivity of an abiological intermediate.

In Vivo Biocatalytic Cascades Featuring an Artificial-Enzyme-Catalysed New-to-Nature Reaction

Artificial enzymes utilizing the genetically encoded non-proteinogenic amino acid p-aminophenylalanine (pAF) as a catalytic residue are able to react with carbonyl compounds through an iminium ion mechanism to promote reactions that have no equivalent in nature. Herein, we report an in vivo biocatalytic cascade that is augmented with such an artificial enzyme-catalysed new-to-nature reaction. The artificial enzyme in this study is a pAF-containing evolved variant of the lactococcal multidrug-resistance regulator, designated LmrR_V15pAF_RMH, which efficiently converts benzaldehyde derivatives produced in vivo into the corresponding hydrazone products inside E. coli cells. These in vivo biocatalytic cascades comprising an artificial-enzyme-catalysed reaction are an important step towards achieving a hybrid metabolism.

Introducing a green nanocatalytic process toward the synthesis of benzo[a]pyrano-[2,3-c]phenazines utilizing copper oxide quantum dot-modified core-shell magnetic mesoporous silica nanoparticles as high throughput and reusable nanocatalysts

In this contribution, a green, simple, efficient, and straightforward nanocatalytic process was developed for the synthesis of benzo[a]pyrano[2,3-c]phenazine derivatives under mild thermal conditions. In this regard, the copper oxide quantum dot-modified magnetic silica mesoporous nanoparticles (M-MSNs/CuO(QDs)) were synthesized by surface modification of M-MSNs with CuO QDs to prepare a highly powerful magnetic core-shell nanocatalyst. The prepared nanocatalyst was then characterized for its functionality, size, morphology, elemental composition, surface area, crystallinity, and magnetic properties. Afterwards, it was applied for the synthesis of benzo[a]pyrano[2,3-c]phenazine derivatives under green reaction conditions. The factors affecting the reaction yield were optimized by the one-factor-at-a-time optimization method. Under obtained optimal conditions, the developed method showed a reaction yield range as high as 86-95% for different derivatives. The reusability studies were performed for indexing the cycling stability of the prepared magnetic nanocatalyst. The results exhibited that the catalytic efficiency of the nanocatalyst was saved for at least 5 operational times, showing high cycling stability of M-MSNs/CuO(QDs). Finally, the catalytic performances of the nanocatalyst was compared with the reported ones, revealing that the M-MSNs/CuO(QDs) presents very better performances toward the synthesis of benzo[a]pyrano[2,3-c]phenazine derivatives than the reported ones.

Enzyme Therapy: Current Challenges and Future Perspectives

In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment. This can be achieved by conventional techniques (ELISA) but also by new promising tools such as microarrays. These assays have gained popularity due to their high-throughput analysis capacity, their simplicity, and their potential to monitor the immune response of patients during enzyme therapies. In this growing field, research is still ongoing to solve current health problems such as COVID-19. Currently, promising therapeutic alternatives using the angiotensin-converting enzyme 2 (ACE2) are being studied to treat COVID-19.

Chemical Catalysis Intervening to Histone Epigenetics

Life emerges from complicated and sophisticated chemical networks comprising numerous biomolecules (e.g., nucleic acids, proteins, sugars, and lipids) and chemical reactions catalyzed by enzymes. Dysregulation of these chemical networks is linked to the emergence of diseases. Our research goal is to develop abiotic chemical catalysts that can intervene into life's chemical networks by complementing, surrogating, or exceeding enzymes in living cells or multicellular organisms such as animals or plants. Mending dysregulated networks in pathological states by the chemical catalysts will lead to a new medicinal strategy, catalysis medicine. This research direction will also advance catalysis science, because highly active and selective chemical catalysts must be developed to promote the intended reactions in a complex mixture of life in aqueous solution at body temperature.Epigenetics exists at the crossroads of chemistry, biology, and medicine and is a suitable field to pursue this idea. Post-translational modifications (PTMs) of histones epigenetically regulate chromatin functions and gene transcription and are intimately related to various diseases. Investigating the functions and cross-talk of histone PTMs is crucial for mechanistic elucidation of diseases and their treatments. We launched a program to develop chemical catalysts enabling endogenous histone modifications in living cells without relying on enzymes. We reported two types of chemical catalyst systems so far for synthetic histone acylation. The first system comprised a DNA-binding oligo-4-dimethylaminopyridine (DMAP) catalyst and a phenyl ester acyl donor, PAc-gly. This system promoted histone hyperacetylation in Xenopus laevis sperm chromatin. Using the thus-synthesized hyperacetylated sperm chromatin, we found a novel relationship between histone acetylation and DNA replication. The second system involved a histone-binding catalyst, LANA-DSH, composed of a catalytic motif (DSH) and a histone-binding peptide ligand (LANA), and thioester acyl donors, including endogenous acyl-CoA. This system regioselectively (i.e., selectively to a lysine residue at a specific position) acylated lysine 120 of histone H2B (H2BK120), a lysine residue proximal to the DSH motif defined by binding of the LANA ligand to a nucleosome substrate. This catalyst system was optimized to achieve H2BK120-selective acetylation in living cells without genetic manipulation. The synthetically introduced H2BK120Ac inhibited enzyme-catalyzed ubiquitination at the same lysine residue, acting as a protecting group. H2BK120Ub is a mark recognized by methyltransferase that plays an essential role in mixed-lineage leukemia (MLL)-rearranged leukemia, suggesting the potential of the catalyst system as an epigenetic tool and a cancer therapy. We also discuss the prospects of chemical catalyst-promoted synthetic epigenetics for future PTM studies and therapeutic uses.